Results 11 to 20 of about 30,227 (301)

Repurposing of Bromocriptine for Cancer Therapy

Frontiers in Pharmacology, 2018
Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Ean-Jeong Seo, Yoshikazu Sugimoto, Henry Johannes Greten, Thomas Efferth   +3 more
doaj   +2 more sources

Bromocriptine and insulin sensitivity in lean and obese subjects

Endocrine Connections, 2016
Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler, H J Verberne, E Brakema, R Tepaske, J Booij, J B Hoekstra, F Holleman   +6 more
doaj   +2 more sources

The Effects of Bromocriptine on Preventing Postpartum Flare in Systemic Lupus Erythematosus Patients from South China

Journal of Immunology Research, 2015
Objective. Prolactin plays an important role on the disease flare of postpartum SLE patients. 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the ...
Qiu Qian, Liang Liuqin, Li Hao, Yuan Shiwen, Zhan Zhongping, Chen Dongying, Lian Fan, Xu Hanshi, Yang Xiuyan, Ye Yujin   +9 more
doaj   +2 more sources

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects [PDF]

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2012
Background: Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM).
Blonde, Lawrence, Bohannon, Nancy, Cincotta, Anthony H., Gaziano, John Michael, Scranton, Richard, Vinik, Aaron   +5 more
core   +2 more sources

Cabergoline Use and Pregnancy Outcomes: A Systematic Review. [PDF]

Birth Defects Res
ABSTRACT Introduction Lack of available expert guidelines leads clinicians to interrupt cabergoline treatment upon confirmation of pregnancy and consider switching to bromocriptine, which is more commonly used during pregnancy but is poorly tolerated.
Otis AS, Brochet MS, Tremblay Z, Balayla J, Dahdouh EM.   +4 more
europepmc   +2 more sources

Contribution of Glutamatergic and GABAergic Mechanisms to the Plasticity-Modulating Effects of Dopamine in the Human Motor Cortex. [PDF]

Hum Brain Mapp
Background: Dopamine modulates cortical excitability and plasticity by influencing glutamate and GABA receptor activity. This study investigates the impact of general dopaminergic activation and D1‐ and D2‐like receptor modulation on transcranial direct current stimulation (tDCS)‐induced plasticity in humans.Methods:• Pharmacological intervention: l ...
Ghanavati E, Salehinejad MA, Beaupain MC, Melo L, Frese A, Kuo MF, Nitsche MA.   +6 more
europepmc   +2 more sources

Microprolactinoma Growth During Pregnancy With Pituitary Tumor Apoplexy: Case Report and Review of the Literature. [PDF]

Case Rep Endocrinol
Prolactinomas are the most prevalent subtype of pituitary adenomas and represent one of the leading etiological factors responsible for amenorrhea and infertility in women. The primary therapeutic approach entails the use of dopamine agonists, which effectively restore fertility.
Introini L, Silva J, Risso M, Mendoza B, Pineyro MM.   +4 more
europepmc   +2 more sources

Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy

European heart journal. Acute cardiovascular care, 2020
Introduction: Acute peripartum cardiomyopathy complicated by cardiogenic shock is a rare but life-threatening disease. A prolactin fragment is considered causal for the pathogenesis of peripartum cardiomyopathy.
J. Sieweke, Tobias J. Pfeffer, D. Berliner, T. König, M. Hallbaum, L. C. Napp, J. Tongers, C. Kühn, J. Schmitto, D. Hilfiker-Kleiner, A. Schäfer, J. Bauersachs   +11 more
semanticscholar   +1 more source

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas

International Journal of Medical Sciences, 2020
Prolactinomas are the most common type of functional pituitary adenoma. Although bromocriptine is the preferred first line treatment for prolactinoma, resistance frequently occurs, posing a prominent clinical challenge. Both the prolactin receptor (PRLR)
Zhengzheng Xiao, Xiaoli Yang, Kun Zhang, Zebin Liu, Zheng Shao, Chaojun Song, Xiaobin Wang, Zhengwei Li   +7 more
semanticscholar   +1 more source

Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy [PDF]

, 2016
No abstract ...
Arrigo, Biteker, Blauwet, Brignole, Burkhoff, Cecconi, Duncker, Elkayam, Ersbøll, Fett, Fett, Forster, Gevaert, Haghikia, Haghikia, Haghikia, Hilfiker-Kleiner, Hilfiker-Kleiner, Hilfiker-Kleiner, Hilfiker-Kleiner, Kao, Labbene, Levy, Maisch, Masip, McNamara, Mebazaa, Mebazaa, Miller, Mouquet, Napp, Neumann, O'Connor, Patten, Pillarisetti, Ponikowski, Rasmusson, Regitz-Zagrosek, Schroeter, Seyfarth, Slaughter, Sliwa, Sliwa, Sliwa, Stapel, Strueber, Thiele, Thiele, Tibazarwa   +48 more
core   +7 more sources